As filed with the Securities and Exchange Commission
on August 10, 2023
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Collegium Pharmaceutical, Inc.
(Exact name of registrant as specified in its charter)
| Virginia |
|
100 Technology Center Drive
Stoughton, MA 02072 |
|
03-0416362 |
(State or other jurisdiction of
incorporation or organization) |
|
(Address, including zip code, of
Principal Executive Offices) |
|
(I.R.S. Employer
Identification No.) |
AMENDED AND RESTATED 2014 STOCK INCENTIVE PLAN
2015 EMPLOYEE STOCK PURCHASE PLAN
(Full title of the plans)
Joseph Ciaffoni
President and Chief Executive Officer
100 Technology Center Drive
Stoughton, MA 02072
(781) 713-3699
(Name, address, including zip code, and telephone
number, including area code, of agent for service)
Copies to:
| Jennifer L. Porter, Esq. |
|
Shirley R. Kuhlmann, Esq. |
| Goodwin Procter LLP |
|
Executive Vice President, |
| 2005 Market Street |
|
General Counsel and Chief Administrative Officer |
| 32nd Floor |
|
100 Technology Center Drive, Suite 300 |
| Philadelphia, PA 19103 |
|
Stoughton, MA 02072 |
| (445) 206-7806 |
|
(781) 713-3699 |
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.
See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”
and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer |
x |
Accelerated filer |
¨ |
| Non-accelerated filer |
¨ |
Smaller reporting company |
¨ |
| |
|
Emerging growth company |
¨ |
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨
EXPLANATORY NOTE
This Registration Statement on Form S-8
is being filed for the purpose of registering an additional 1,692,446 shares of Common Stock of the Registrant that were added to
the shares authorized for issuance under the Collegium Pharmaceutical, Inc. Amended and Restated 2014 Stock Incentive Plan (the
“Stock Incentive Plan”) and the Collegium Pharmaceutical, Inc. 2015 Employee Stock Purchase Plan (the
“ESPP”) for which a Registration Statement on Form S-8 relating to the same employee benefit plans is effective.
Pursuant to General Instruction E to Form S-8, the contents of the Registration Statements on Form S-8 (File Nos.
333-207744, 333-218767, 333-225498, 333-233092, 333-245649, 333-258752 and 333-266778) filed with the Securities and Exchange
Commission (the “Commission”) on November 2,
2015, June 15,
2017, June 7,
2018, August 7,
2019, August 13,
2020, August 12,
2021, and August 11,
2022 are incorporated herein by reference except to the extent supplemented, amended or superseded by the information set
forth herein. Only those items of Form S-8 containing new information not contained in the earlier registration statements are
presented herein.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
The following documents of the Registrant filed
with the Commission are incorporated by reference in this Registration Statement as of their respective dates:
| |
(b) |
The Registrant’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2023 and June 30, 2023, filed with the Commission on May 4, 2023 and August 3, 2023, respectively; |
All documents subsequently filed by the Registrant
pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment which indicates
that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated
by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that
documents or information deemed to have been furnished and not filed in accordance with Commission rules shall not be deemed incorporated
by reference into this Registration Statement. Any statement contained herein or in a document, all or a portion of which is incorporated
or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this Registration Statement
to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated
by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as
so modified or amended, to constitute a part of this Registration Statement.
Item 8. Exhibits.
(1) Previously filed as an exhibit to the Registrant’s Quarterly
Report on Form 10-Q, filed with the Commission on August 5, 2020.
(2) Previously filed as an exhibit to the Registrant’s Current
Report on Form 8-K filed with the Commission on December 4, 2017.
(3) Previously filed as an exhibit to the Registrant’s Registration
Statement on Form S-8 (File No. 333-207744) filed with the Commission on November 2, 2015.
(4) Previously filed as an exhibit to the Registrant’s Quarterly
Report on Form 10-Q, filed with the Commission on May 8, 2019.
SIGNATURES
Pursuant to the requirements of the Securities
Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for
filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly
authorized, in the Town of Stoughton, Commonwealth of Massachusetts, on this 10th day of August, 2023.
| |
COLLEGIUM PHARMACEUTICAL, INC. |
| |
|
| |
By: |
/s/ Joseph Ciaffoni |
| |
|
Joseph Ciaffoni |
| |
|
President and Chief Executive Officer |
POWER OF ATTORNEY
We, the undersigned officers and directors of Collegium
Pharmaceutical, Inc., hereby severally constitute and appoint Joseph Ciaffoni, Colleen Tupper and Shirley R. Kuhlmann, and each of
them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities
indicated below, the Registration Statement on Form S-8 filed herewith and any and all subsequent amendments to said Registration
Statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Collegium
Pharmaceutical, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities
and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to
said Registration Statement and any and all amendments thereto.
Pursuant to the requirements of the Securities
Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the capacities indicated
on August 10th , 2023.
| |
Signature |
|
Title |
| |
|
|
|
| |
/s/ Joseph Ciaffoni |
|
President and Chief Executive Officer (Principal Executive Officer) and Director |
| |
Joseph Ciaffoni |
|
| |
|
|
|
| |
/s/ Colleen Tupper |
|
Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) |
| |
Colleen Tupper |
|
| |
|
|
|
| |
/s/ Michael T. Heffernan, R.Ph. |
|
Chairman of the Board and Director |
| |
Michael T. Heffernan, R.Ph. |
|
|
| |
|
|
|
| |
/s/ Rita Balice-Gordon, Ph.D. |
|
Director |
| |
Rita Balice-Gordon, Ph.D. |
|
|
| |
|
|
|
| |
/s/ Garen G. Bohlin |
|
Director |
| |
Garen G. Bohlin |
|
|
| |
|
|
|
| |
/s/ John A. Fallon, M.D. |
|
Director |
| |
John A. Fallon, M.D. |
|
|
| |
|
|
|
| |
/s/ John G. Freund, M.D. |
|
Director |
| |
John G. Freund, M.D. |
|
|
| |
|
|
|
| |
/s/ Neil F. McFarlane |
|
Director |
| |
Neil F. McFarlane |
|
|
| |
|
|
|
| |
/s/ Gwen A. Melincoff |
|
Director |
| |
Gwen A. Melincoff |
|
|
| |
|
|
|
| |
/s/ Gino Santini |
|
Director |
| |
Gino Santini |
|
|
Exhibit 5.1
| Troutman Pepper Hamilton Sanders LLP |
 |
| Troutman Sanders Building, 1001 Haxall Point |
| Richmond, VA 23219 |
| |
| troutman.com |
August 10, 2023
Board of Directors
Collegium Pharmaceutical, Inc.
100 Technology Center Drive, Suite 300
Stoughton, MA 02072
Re: Registration Statement on Form S-8
Ladies and Gentlemen:
Reference is made to the registration statement
on Form S-8 (the “Registration Statement”) of Collegium Pharmaceutical, Inc., a Virginia corporation (the “Company”),
filed on the date hereof with the Securities and Exchange Commission (the “Commission”) under the Securities Act of
1933, as amended (the “Act”). The Registration Statement covers an aggregate of 1,692,446 shares of the Company’s
Common Stock, par value $0.001 per share (the “Common Stock”), including (i) 1,353,957 shares of Common Stock (the
“2014 Plan Shares”) pursuant to the Company’s Amended and Restated 2014 Stock Incentive Plan (the “2014
Plan”), and (ii) 338,489 shares of Common Stock (the “2015 ESPP Shares”, and together with the 2014 Plan
Shares, the “Shares”) pursuant to the Company’s 2015 Employee Stock Purchase Plan (the “2015 ESPP”,
and together with the 2014 Plan, the “Plans”). This opinion letter is furnished in accordance with the requirements
of Item 8(a) of Form S-8 and Item 601(b)(5)(i) of Regulation S-K.
For purposes of this opinion letter, we have examined
the Registration Statement, including the exhibits thereto, the originals or copies, certified or otherwise identified to our satisfaction,
of the Third Amended and Restated Articles of Incorporation (the “Articles of Incorporation”) and the Amended and Restated
Bylaws of the Company, the Plans and such agreements, instruments and documents as we have deemed an appropriate basis on which to render
the opinions hereinafter expressed. In our examination of the aforesaid documents, we have assumed the genuineness of all signatures,
the legal competence and capacity of all natural persons, the accuracy and completeness of all documents submitted to us, the authenticity
of all original documents, and the conformity to authentic original documents of all documents submitted to us as copies (including telecopies).
As to all matters of fact, we have relied on the representations and statements of fact made in the documents so reviewed, and we have
not independently established the facts so relied on. This opinion letter is given, and all statements herein are made, in the context
of the foregoing.
In connection herewith, we have assumed that all
of the documents referred to in this opinion letter have been duly authorized by, have been duly executed and delivered by, and constitute
the valid, binding and enforceable obligations of, all of the parties to such documents, all of the signatories to such documents have
been duly authorized and all such parties are duly organized and validly existing and have the power and authority (corporate or other)
to execute, deliver and perform such documents.
We do not purport to express an opinion on any
laws other than the laws of the Commonwealth of Virginia. The opinions set forth herein are made as of the date hereof and are subject
to, and may be limited by, future changes in the factual matters set forth herein, and we undertake no duty to advise you of the same.
The opinions expressed herein are based upon the law in effect (and published or otherwise generally available) on the date hereof, and
we assume no obligation to revise or supplement these opinions should such law be changed by legislative action, judicial decision or
otherwise. In rendering our opinions, we have not considered, and hereby disclaim any opinion as to, the application or impact of any
laws, cases, decisions, rules or regulations of any other jurisdiction, court or administrative agency.
Based upon the foregoing and in reliance thereon,
and subject to the assumptions, comments, qualifications, limitations and exceptions set forth herein, we are of the opinion that the
Shares have been duly authorized for issuance, and when issued, delivered and paid for in accordance with the Plans (assuming that, upon
any issuance of the Shares, the total number of shares of common stock issued and outstanding will not exceed the total number of shares
of common stock that the Company is then authorized to issue under its Articles of Incorporation), the Shares will be legally issued,
fully paid and non-assessable.
August 10, 2023
Page 2 | |
We do not render any opinions
except as set forth above. We hereby consent to the filing of this opinion as Exhibit 5.1 to the Registration Statement. We also consent
to your filing copies of this opinion as an exhibit to the Registration Statement with such agencies of such states as you deem necessary
in the course of complying with the laws of such states regarding the offering and sale of the securities addressed herein. In giving
this consent, we do not admit that we are within the category of persons whose consent is required by Section 7 of the Securities Act
or the rules and regulations promulgated thereunder by the Commission.
| |
Very truly yours, |
| |
|
| |
/s/ Troutman Pepper Hamilton Sanders LLP |
| |
|
| |
Troutman Pepper Hamilton Sanders LLP |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM
We consent to the incorporation
by reference in this Registration Statement on Form S-8 of our reports dated February 23, 2023, relating to the financial statements
of Collegium Pharmaceutical, Inc. and the effectiveness of Collegium Pharmaceutical, Inc.’s internal control over financial
reporting, appearing in the Annual Report on Form 10-K of Collegium Pharmaceutical, Inc. for the year ended December 31,
2022.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
August 10, 2023
Exhibit 107
CALCULATION OF FILING FEE TABLES
Form S-8
(Form Type)
Collegium Pharmaceutical, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
| Security Type | |
Security Class Title | |
Fee Calculation Rule | |
Amount
Registered (1) | | |
Proposed
Maximum
Offering
Price Per
Share (2) | | |
Maximum
Aggregate
Offering
Price | | |
Fee Rate | | |
Amount
Of
Registration
Fee | |
| Equity | |
Common Stock, $0.001 par value per share – Amended and Restated 2014 Stock Incentive Plan | |
457(c) and 457(h) | |
| 1,353,957 | (3) | |
$ | 21.94 | | |
$ | 29,705,816.58 | | |
| .00011020 | | |
$ | 3,273.58 | |
| Equity | |
Common Stock, $0.001 par value per share – 2015 Employee Stock Purchase Plan | |
457(c) and 457(h) | |
| 338,489 | (4) | |
$ | 21.94 | | |
$ | 7,426,448.66 | | |
| .00011020 | | |
$ | 818.39 | |
| | |
Total Offering Amounts | |
| |
| 1,692,446 | | |
| — | | |
$ | 37,132,265.24 | | |
| | | |
$ | 4,091.97 | |
| | |
Total Fee Offsets (5) | |
| |
| | | |
| | | |
| | | |
| | | |
| --- | |
| | |
Net Fee Due | |
| |
| | | |
| | | |
| | | |
| | | |
$ | 4,091.97 | |
(1) In accordance with Rule 416 under the Securities Act
of 1933, as amended, this Registration Statement on Form S-8 shall be deemed to cover any additional shares of common stock, $0.001
par value per share (the “Common Stock”), of Collegium Pharmaceutical, Inc., a Virginia corporation (the “Registrant”),
which become issuable under the above-named plans by reason of any stock dividend, stock split, recapitalization or other similar transaction
effected without the receipt of consideration which results in an increase in the number of the outstanding shares of Common Stock of
the Registrant. Pursuant to Rule 416(c) under the Securities Act, this registration statement shall also cover an indeterminate
amount of interests to be offered or sold pursuant to the Collegium Pharmaceutical, Inc. 2015 Employee Stock Purchase Plan (the “ESPP”).
(2) Estimated in accordance with Rule 457(c) and Rule 457(h) solely
for the purpose of calculating the registration fee on the basis of the average of the high and low prices of the Registrant’s common
stock as reported on The Nasdaq Global Select Market on August 3, 2023.
(3) Represents 1,353,957 shares of Common Stock of the Registrant
that were added to the shares authorized for issuance under the Collegium Pharmaceutical, Inc. Amended and Restated 2014 Stock Incentive
Plan (the “Stock Incentive Plan”) on January 1, 2023, pursuant to an “evergreen” provision contained in the
Stock Incentive Plan. Pursuant to such provision in the Stock Incentive Plan, as of the first day of each fiscal year, from January 1,
2016 until the expiration of the Stock Incentive Plan, the number of shares authorized for issuance under the Stock Incentive Plan is
increased by a number of shares of Common Stock equal to 4% of the total number of outstanding shares of Common Stock on December 31st
of the immediately preceding calendar year or such lesser number of shares of Common Stock as determined by the Board of Directors of
the Registrant.
(4) Represents 338,489 shares of Common Stock of the Registrant
that were added to the shares authorized for issuance under the ESPP on January 1, 2023, pursuant to an “evergreen”
provision contained in the ESPP. Pursuant to such provision in the ESPP, as of the first day of each fiscal year, from January 1,
2016 until December 31, 2025, the number of shares authorized for issuance under the ESPP is increased by a number equal to the
least of (i) 400,000 shares of Common Stock, (ii) 1% of the outstanding shares of Common Stock on such date or (iii) an
amount determined by the Board of Directors of the Registrant.
(5) The Registrant does not have any fee offsets.
Collegium Pharmaceutical (NASDAQ:COLL)
Historical Stock Chart
From Apr 2024 to May 2024
Collegium Pharmaceutical (NASDAQ:COLL)
Historical Stock Chart
From May 2023 to May 2024
